Circumventing the Blood-Testis Barrier
绕过血睾屏障
基本信息
- 批准号:9329790
- 负责人:
- 金额:$ 29.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2020-12-31
- 项目状态:已结题
- 来源:
- 关键词:ABCC1 geneAcute Lymphocytic LeukemiaAffectAmilorideAnatomyAntiviral AgentsApicalBiological AssayBiologyBloodBlood - brain barrier anatomyBlood VesselsBlood-Testis BarrierBypassCellsClofarabineComputer SimulationComputing MethodologiesContraceptive methodsCytarabineDataDevelopmentDidanosineDiseaseDrug Delivery SystemsDrug usageEpididymisEpithelialEpithelial CellsEquilibrative Nucleoside Transporter 1Fertility AgentsFoundationsFrequenciesGenerationsGoalsGrantHIVHIV InfectionsHormonesHumanImmunohistochemistryIndinavirInfertilityKnockout MiceLamivudineLibrariesMale Genital OrgansMolecularMusNatureNelarabineNucleosidesOrchiectomyOrganOsmosisOutcomePathway interactionsPatientsPenetrationPharmaceutical PreparationsPharmacologyPharmacotherapyProcessProstateRelapseReverse Transcriptase InhibitorsRoleSeminal VesiclesSiteSodiumSperm MaturationSystemTenofovirTestingTestisTherapeuticTherapeutic EffectTherapeutic InterventionTight JunctionsTissuesTransport ProcessUnited States National Institutes of HealthWaterWorkXenobioticsZalcitabineZidovudineabacavirbasecarrier mediated transportchemotherapydesigndrug developmentgene therapyhydrophilicityimprovedin vivoinsightirradiationleukemiamonolayernovelnovel therapeuticsnucleoside analogpredictive modelingreproductivereproductive tractsertoli cellsperm celltherapeutic targettherapy developmenttransmission processuptake
项目摘要
PROJECT SUMMARY
The testis and epididymis mark the initial portion of the male genital tract (MGT) and are
impermeable to most hydrophilic compounds due to tight junctions. This barrier ─ the blood-
testes barrier (BTB) ─ can act as an obstacle for therapies requiring entry into these tissues for
full effect; for example contributing to testicular relapse in acute lymphoblastic leukemia (ALL)
or acting as a sanctuary site for HIV infection. However, these epithelial barriers are known to
express alternative xenobiotic transporters that may be utilized to allow select agents to gain
access to the MGT and reduce the frequency of testicular relapse or HIV transmission. Rather
than studying why drugs fail to cross the BTB, the major focus of our studies is to characterize the
endogenous transport processes that could allow drugs to access the MGT. We hypothesize that
the penetration of MGT relevant drugs into the BTB occurs through transport processes that can
be modeled computationally, and that therapeutic concentration of these drugs is greatly affected
by epididymal transporters and water reabsorption. Our grant focuses on 3 aims: Aim 1: Establish
the transepithelial transport mechanisms by which MGT relevant drugs can cross the BTB and
develop a predictive model for rational therapeutic design. Aim 2: Determine the impact of
epididymal water reabsorption on drug concentrations within the MGT in vivo. Aim 3: Determine
whether nucleoside transport is supported in the epididymis and the impact on nucleoside-based
drug disposition. Understanding these pathways will be foundational for the development of
drugs, such as antiviral, chemotherapy, contraception, and fertility agents, that require access to
the MGT in order to achieve full therapeutic effect.
项目摘要
睾丸和附睾标志着男性生殖道(MGT)的起始部分,
由于紧密连接,对大多数亲水化合物是不可渗透的。这个屏障-血液-
睾丸屏障(BTB)-可以作为需要进入这些组织的治疗的障碍,
完全效应;例如,导致急性淋巴细胞白血病(ALL)睾丸复发
或者成为艾滋病病毒感染的避难所然而,已知这些上皮屏障
表达可用于允许选择性试剂获得的替代性异生素转运蛋白
获得MGT和减少睾丸复发或艾滋病毒传播的频率。而
我们研究的主要重点是描述药物不能穿过BTB的原因,
内源性运输过程,可以让药物进入MGT。我们假设
MGT相关药物通过转运过程进入BTB,
可以通过计算建模,并且这些药物的治疗浓度受到很大影响
通过附睾转运蛋白和水重吸收。我们的赠款侧重于3个目标:目标1:建立
MGT相关药物可穿过BTB的跨上皮转运机制,
为合理的治疗设计开发预测模型。目标2:确定
附睾水重吸收对体内MGT内药物浓度的影响。目标3:确定
核苷转运是否在附睾中得到支持,以及对基于核苷的
药物处置了解这些途径将是发展
药物,如抗病毒,化疗,避孕和生育剂,需要获得
MGT,以达到充分的治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathan J Cherrington其他文献
Nathan J Cherrington的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nathan J Cherrington', 18)}}的其他基金
MegaTrans – human transporter machine learning models
MegaTrans — 人类运输机机器学习模型
- 批准号:
10546264 - 财政年份:2019
- 资助金额:
$ 29.55万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 29.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 29.55万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 29.55万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 29.55万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 29.55万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 29.55万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 29.55万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 29.55万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 29.55万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 29.55万 - 项目类别: